WEBULL
WebtradeDownload

Why Is Bayer (XTRA:BAYN) Seeking A Wider CKD Use For KERENDIA?

Simply Wall St · 1d ago
  • Bayer (XTRA:BAYN) reported that the U.S. FDA has accepted its supplemental New Drug Application for KERENDIA to treat CKD in adults without diabetes.
  • The application is supported by data from the Phase III FIND-CKD trial evaluating finerenone in patients with chronic kidney disease.
  • KERENDIA is already approved in the U.S. for adults with chronic kidney disease associated with type 2 diabetes, so this filing targets a broader patient group.
  • The FDA’s acceptance of Bayer’s KERENDIA filing for non diabetic CKD is a fresh development to weigh alongside our other work. Take a look at 4 other big wins we have identified for Bayer.

For readers looking to widen their watchlists beyond Bayer and into adjacent treatment themes, the next stop is 124 healthcare AI stocks.

XTRA:BAYN Earnings & Revenue Growth as at Oct 2026
XTRA:BAYN Earnings & Revenue Growth as at Oct 2026

Bayer operates as a global life science group across Europe, the Middle East, Africa, North America, the Asia Pacific and Latin America, so an expanded KERENDIA label would plug into an existing worldwide footprint in kidney and metabolic care. The business already runs a pharmaceuticals division focused on chronic conditions, which gives this kidney disease program a built-in commercial and clinical infrastructure.

How big could the non diabetic CKD market be for KERENDIA?

Chronic kidney disease without diabetes covers a broad mix of causes, from glomerular disease to hypertensive nephropathy, and the FIND CKD trial enrolled 1,584 such patients on top of existing standard of care. For Bayer, that points to a treatment arena that sits alongside, rather than overlapping with, the existing diabetes linked CKD approvals. This widens the addressable pool for finerenone based therapy inside its renal and cardiovascular franchise.

Does this change the Bayer Narrative investors have been tracking?

The Narrative around Bayer centers on its pharma pipeline helping offset pressure from older drugs, with KERENDIA already listed as a key launch alongside assets like Lynkuet. FDA acceptance of this sNDA, backed by positive Phase III data and a safety profile in line with prior studies, supports the view that new labels and indications can deepen the pharmaceuticals arm rather than leaving it reliant on legacy products.

See how these catalysts shape Bayer's path to a €58.22 fair value.

What is the one signpost to watch next on this KERENDIA read?

The critical marker now is the FDA decision on this sNDA, including any label language around the non diabetic CKD population and required monitoring. Timing of that ruling, plus any guidance Bayer gives on how it might supply and support additional CKD demand from its planned New Albany facility, will help test the current read on market opportunity and execution.

The next Bayer checkpoint many investors run before moving

Before you act on any product story, it often pays to see who is actually in charge at Bayer, how their incentives are wired, and what that might nudge them to prioritise. See who is actually steering Bayer, and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.